Pfizer: One of the world's premier biopharmaceutical companies

Shot of a Lifetime

Our Products

Shot of a Lifetime

How Pfizer and BioNTech Developed and Manufactured a COVID-19 Vaccine in Record Time

FIND OUT HOW WE DID IT

Raising Health Literate Children

Your Health

Raising Health Literate Children

Why starting young can mean better health outcomes later in life.

Visit Our COVID-19 Hub

Our Science

Visit Our COVID-19 Hub

What you need to know about the virus and updates on how Pfizer is responding to the crisis.

VISIT OUR RESOURCES

Cold, Flu, COVID-19, or Stomach Bug

Your Health

Cold, Flu, COVID-19, or Stomach Bug

If you're feeling sick this fall, here's how to tell the difference between these common illnesses.

Learn More

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Your search for a clinical trial starts here.

Learn more about the process of joining a clinical trial and find a trial near you.

Start now

LEARN ABOUT OUR CLINICAL TRIAL FOR PEOPLE RECENTLY DIAGNOSED WITH COVID-19

Our Science

LEARN ABOUT OUR CLINICAL TRIAL FOR PEOPLE RECENTLY DIAGNOSED WITH COVID-19

Do you have COVID-19? We are currently enrolling participants in a clinical trial for a potential oral treatment option.

See If You Qualify

The Truth About COVID-19 and "Black Fungus"

Your Health

The Truth About COVID-19 and "Black Fungus"

Setting the record straight about a rare but fatal infection

Learn More

Latest News

Pfizer’s Abrocitinib Receives Positive CHMP…

CHMP also recommends XELJANZ® (tofacitinib) approval for the treatment of adults with active ankylosing spondylitis Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis (AD) in adults who are…